国药现代(600420) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was RMB 9,363,062,749.56, a decrease of 14.40% compared to RMB 10,937,525,114.43 in the previous year[4] - Net profit attributable to shareholders was RMB 944,379,815.55, down 12.85% from RMB 1,083,622,881.88 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 851,780,585.11, a decline of 18.36% from RMB 1,043,284,677.64 year-on-year[4] - Basic earnings per share decreased to RMB 0.7041 from RMB 0.8080, a decline of 12.86%[4] Profitability and Margins - The gross profit margin decreased by 6.91 percentage points due to price fluctuations and competitive pressures in the pharmaceutical intermediate and raw material sectors[6] - The company reported an increase in non-recurring gains of RMB 52,261,000, which contributed to the overall financial performance despite the decline in net profit[6] Cost Management - The company achieved a reduction in operating expense ratio by 3.68 percentage points compared to the previous year, reflecting effective cost control measures[6] Assets and Equity - Total assets at the end of the reporting period were RMB 19,229,491,609.33, a decrease of 3.64% from RMB 19,955,597,470.69 at the beginning of the period[4] - Shareholders' equity attributable to the company increased by 4.38% to RMB 13,781,619,993.70 from RMB 13,203,924,172.51[4] Strategic Focus - The company is focusing on transforming its marketing model and enhancing efficiency to stabilize operations amid challenging market conditions[7]